![]()
|
|
||||||||
Vol. 273, Issue 1, 256-261, January 2, 1998
From the Protein Engineering Research Group, Korea Research
Institute of Bioscience and Biotechnology, KIST, P. O. Box
115, Yusong, Taejon 305-600, Korea
Thrombopoietin (TPO) is a megakaryocyte growth
and differentiation factor. It consists of a characteristic two
domain structure. The amino-terminal domain of TPO has a sequence
homology with erythropoietin and is required for the binding and
activation of its receptor c-Mpl. To determine the functionally
important regions interacting with its receptor, a series of
site-directed mutants of TPO were constructed based on a
three-dimensional model of the amino-terminal domain. Two strategies of
mutagenesis were employed: 1) nonnative N-linked
glycosylation scan of 12 residues predicted to be on the surface, and
2) alanine replacement scan of mostly charged 44 amino acid residues.
Each TPO mutein was transiently expressed in COS7 cells, and the
specific bioactivity of the TPO protein secreted into the culture
medium was measured using a recombinant BaF3 cell line expressing human
c-Mpl. Four alanine substitutions at Arg10,
Pro42, Glu50, and Lys138 nearly or
completely abolished the activity, whereas the mutation at
Arg14 slightly decreased the activity, suggesting that
these residues are functionally important in interacting with its
receptor. These residues mapped to helix A, loop AB, and helix D. Sequence comparison between human TPO and other mammalian TPO showed
that the identified residues are completely conserved among the
species. However, unlike the recent report on the mutational analysis
of TPO, alanine substitutions at Lys52, Lys59,
Arg136, and Arg140 did not affect the TPO
activity significantly in our system. The identified receptor binding
regions of TPO are analogous to those of human growth hormone and
erythropoietin. Based on the similarity of these three cytokines, we
propose that Lys138 of helix D and Pro42 and
Glu50 of loop AB may constitute one binding region, whereas
Arg10 and Lys14 of helix A may constitute the
other binding region to dimerize the receptors.
This article has been cited by other articles:
![]() |
M. D. Feese, T. Tamada, Y. Kato, Y. Maeda, M. Hirose, Y. Matsukura, H. Shigematsu, T. Muto, A. Matsumoto, H. Watarai, et al. Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment PNAS, February 17, 2004; 101(7): 1816 - 1821. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. McClure, F. Stomski, A. Lopez, and J. Woodcock Perverted responses of the human granulocyte-macrophage colony-stimulating factor receptor in mouse cell lines due to cross-species beta -subunit association Blood, November 15, 2001; 98(10): 3165 - 3168. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. D. COOPER and G. J. SPANGRUDE (R)Evolutionary Considerations in Hematopoietic Development Ann. N.Y. Acad. Sci., April 30, 1999; 872(1): 83 - 93. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kato, A. Matsumoto, K. Ogami, T. Tahara, H. Morita, and H. Miyazaki Native Thrombopoietin: Structure and Function Stem Cells, September 1, 1998; 16(5): 322 - 328. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |